NOVATO, Calif., Jan. 4, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced that Christopher M. Starr, Ph.D., Raptor's Chief Executive Officer, will present an overview of the Company at the 30th Annual JP Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel. Raptor's presentation will take place on Thursday, January 12, 2012, beginning at 12:00 p.m. PT.
A live audio webcast and 14-day archive of the presentation may be accessed via the Investors and Media section of Raptor's website www.raptorpharma.com.
In addition, Raptor is hosting an event providing an overview of its non-alcoholic steatohepatitis ("NASH") program on Tuesday, January 10, 2012 at 4:30pm PT in San Francisco during the JP Morgan Healthcare Conference. This event will include Raptor's management along with Jeffrey Schwimmer, M.D., an expert in NASH. Dr. Schwimmer is Director of the Weight and Wellness Center at Rady Children's Hospital-San Diego and an investigator on Raptor's planned Phase 2b clinical trial in NASH in collaboration with the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health. The Company will provide a teleconference feed for those not attending the conference. To attend or call into the event, please contact Lauren Glaser at lglaser@troutgroup.com.
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ("Raptor") seeks to research, produce, and deliver medicines that improve life for patients with severe, rare disorders. Raptor currently has product candidates in clinical development designed to potentially treat nephropathic cystinosis, Non-alcoholic Steatohepatitis ("NASH"), Huntington's Disease ("HD"), aldehyde dehydrogenase deficiency ("ALDH2"), and thrombotic disorder.
Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein and related proteins that are designed to target cancer and infectious diseases.
For additional information, please visit www.raptorpharma.com.
The Raptor Pharmaceutical Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7180